The promise of retinoids to fight against cancer (original) (raw)

• Niederreither, K., Subbarayan, V., Dolle, P. & Chambon, P. Embryonic retinoic acid synthesis is essential for early mouse post-implantation development. Nature Genet. 21, 444–448 (1999).Targeted gene disruption shows that production of retinoic acid by the retinaldehyde dehydrogenase-2 (Raldh2) enzyme is required for mouse embryo survival and early morphogenesis.
  Article CAS PubMed Google Scholar
• de Urquiza, A. M. et al. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 290, 2140–2144 (2000).Identification of brain-derived docosahexaenoic acid as an RXR ligand.
  Article CAS PubMed Google Scholar
• Krezel, W. et al. Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science 279, 863–867 (1998).
  Article CAS PubMed Google Scholar
• Kastner, P. et al. Abnormal spermatogenesis in RXRβ mutant mice. Genes Dev. 10, 80–92 (1996).
  Article CAS PubMed Google Scholar
• Massaro, G. D. et al. Retinoic acid receptor-β: an endogenous inhibitor of the perinatal formation of pulmonary alveoli. Physiol. Genomics 4, 51–57 (2000).
  Article CAS PubMed Google Scholar
• Wan, Y. J. et al. Hepatocyte-specific mutation establishes retinoid X receptor-α as a heterodimeric integrator of multiple physiological processes in the liver. Mol. Cell Biol. 20, 4436–4444 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Imai, T., Jiang, M., Kastner, P., Chambon, P. & Metzger, D. Selective ablation of retinoid X receptor-α in hepatocytes impairs their lifespan and regenerative capacity. Proc. Natl Acad. Sci. USA 98, 4581–4586 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Dupe, V. et al. Essential roles of retinoic acid signaling in interdigital apoptosis and control of BMP-7 expression in mouse autopods. Dev. Biol. 208, 30–43 (1999).
  Article CAS PubMed Google Scholar
• Altucci, L. et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand trail. Nature Med. 7, 680–686 (2001).Retinoic-acid therapy of acute promyelocytic leukaemia involves induction of cell differentiation linked to early-induced anti-apoptotic gene programming, which is followed by post-differentiation apoptosis caused by activation of the TRAIL signalling pathway.
  Article CAS PubMed Google Scholar
• Kastner, P. et al. Genetic evidence that the retinoid signal is transduced by heterodimeric RXR/RAR functional units during mouse development. Development 124, 313–326 (1997).
  Article CAS PubMed Google Scholar
• Chen, J. Y. et al. RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 14, 1187–1197 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Arnhold, T., Tzimas, G., Wittfoht, W., Plonait, S. & Nau, H. Identification of 9-_cis_-retinoic acid, 9,13-di-_cis_-retinoic acid, and 14-hydroxy-4,14-_retro_-retinol in human plasma after liver consumption. Life Sci. 59, L169–L177 (1996).
  Article Google Scholar
• Buck, J., Derguini, F., Levi, E., Nakanishi, K. & Hammerling, U. Intracellular signaling by 14-hydroxy-4,14-_retro_-retinol. Science 254, 1654–1656 (1991).
  Article CAS PubMed Google Scholar
• Bourguet, W. et al. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol. Cell 5, 289–298 (2000).
  Article CAS PubMed Google Scholar
• Jepsen, K. et al. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102, 753–763 (2000).
  Article CAS PubMed Google Scholar
• Bourguet, W., Germain, P. & Gronemeyer, H. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol. Sci. 21, 381–388 (2000).
  Article CAS PubMed Google Scholar
• Glass, C. K. & Rosenfeld, M. G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14, 121–141 (2000).
  CAS PubMed Google Scholar
• Rachez, C. & Freedman, L. P. Mediator complexes and transcription. Curr. Opin. Cell Biol. 13, 274–280 (2001).
  Article CAS PubMed Google Scholar
• Ito, M. & Roeder, R. G. The TRAP/SMCC/mediator complex and thyroid hormone receptor function. Trends Endocrinol. Metab. 12, 127–134 (2001).
  Article CAS PubMed Google Scholar
• Benoit, G. et al. RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J. 18, 7011–7018 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Benoit, G. R. et al. Autonomous rexinoid death signaling is suppressed by converging signaling pathways in immature leukemia cells. Mol. Endocrinol. 15, 1154–1169 (2001).Together with reference 20 , this is the first demonstration of autonomous rexinoid signalling.
  Article CAS PubMed Google Scholar
• Kastner, P., Mark, M. & Chambon, P. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell 83, 859–869 (1995).
  Article CAS PubMed Google Scholar
• Pasqualetti, M., Neun, R., Davenne, M. & Rijli, F. M. Retinoic acid rescues inner ear defects in Hoxa1 deficient mice. Nature Genet. 29, 34–39 (2001).
  Article CAS PubMed Google Scholar
• Fisher, G. J. & Voorhees, J. J. Molecular mechanisms of retinoid actions in skin. FASEB J. 10, 1002–1013 (1996).
  Article CAS PubMed Google Scholar
• Massaro, G. D. & Massaro, D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nature Med. 3, 675–677 (1997).
  Article CAS PubMed Google Scholar
• Gerster, H. Vitamin A: functions, dietary requirements and safety in humans. Int. J. Vitam. Nutr. Res. 67, 71–90 (1997).
  CAS PubMed Google Scholar
• Corcoran, J. & Maden, M. Nerve growth factor acts via retinoic acid synthesis to stimulate neurite outgrowth. Nature Neurosci. 2, 307–308 (1999).
  Article CAS PubMed Google Scholar
• Mollard, R., Ghyselinck, N. B., Wendling, O., Chambon, P. & Mark, M. Stage-dependent responses of the developing lung to retinoic acid signaling. Int. J. Dev. Biol. 44, 457–462 (2000).
  CAS PubMed Google Scholar
• Widschwendter, M. et al. Methylation and silencing of the retinoic acid receptor-β2 gene in breast cancer. J. Natl Cancer Inst. 92, 826–832 (2000).Studies in breast cancer cell lines and patient biopsies indicate that methylation of the RARβ2 gene might be an initial step in breast carcinogenesis. This study indicates that treatment with demethylating agents followed by retinoic acid might offer a new therapeutic modality.
  Article CAS PubMed Google Scholar
• Bovenzi, V. & Momparler, R. L. Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor-β and estrogen receptor-α genes in breast carcinoma cells. Cancer Chemother. Pharmacol. 48, 71–76 (2001).
  Article CAS PubMed Google Scholar
• Lin, B. et al. Orphan receptor COUP-TF is required for induction of retinoic acid receptor-β, growth inhibition, and apoptosis by retinoic acid in cancer cells. Mol. Cell Biol. 20, 957–970 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Wong, C. W. & Privalsky, M. L. Transcriptional silencing is defined by isoform- and heterodimer-specific interactions between nuclear hormone receptors and corepressors. Mol. Cell Biol. 18, 5724–5733 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Germain, P., Iyer, J., Zechel, C. & Gronemeyer, H. Coregulator recruitment and the mechanism of retinoic acid receptor synergy. Nature (in the press).
• Lin, F., Xiao, D., Kolluri, S. K. & Zhang, X. Unique anti-activator protein-1 activity of retinoic acid receptor-β. Cancer Res. 60, 3271–3280 (2000).
  CAS PubMed Google Scholar
• Dong, Z., Birrer, M. J., Watts, R. G., Matrisian, L. M. & Colburn, N. H. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc. Natl Acad. Sci. USA 91, 609–613 (1994).Retinoic acid inhibits TPA-induced transformation and anchorage-independent cell growth in the dose range that blocks TPA-induced AP-1 activity, indicating (as in reference 11 ) that its prevention of tumour promotion might occur through inhibition of AP1 activity.
  Article CAS PubMed PubMed Central Google Scholar
• Greenhalgh, D. A., Welty, D. J., Player, A. & Yuspa, S. H. Two oncogenes, v-fos and v-ras, cooperate to convert normal keratinocytes to squamous cell carcinoma. Proc. Natl Acad. Sci. USA 87, 643–647 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Leder, A., Kuo, A., Cardiff, R. D., Sinn, E. & Leder, P. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc. Natl Acad. Sci. USA 87, 9178–9182 (1990).A transgenic mouse strain carrying the activated v- HRAS oncogene developed papillomas, some of which went on to develop squamous-cell carcinomas and, more frequently, sarcomas, following treatment with the tumour promoter TPA. Retinoic acid markedly delayed, reduced and often completely inhibited the appearance of TPA-induced papillomas.
  Article CAS PubMed PubMed Central Google Scholar
• Göttlicher, M., Heck, S. & Herrlich, P. Transcriptional cross-talk, the second mode of steroid hormone receptor action. J. Mol. Med. 76, 480–489 (1998).
  Article PubMed Google Scholar
• Resche-Rigon, M. & Gronemeyer, H. Therapeutic potential of selective modulators of nuclear receptor action. Curr. Opin. Chem. Biol. 2, 501–507 (1998).
  Article CAS PubMed Google Scholar
• Fanjul, A. et al. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 372, 107–111 (1994).
  Article CAS PubMed Google Scholar
• Chen, J. Y. et al. Two distinct actions of retinoid-receptor ligands. Nature 382, 819–822 (1996).
  Article CAS PubMed Google Scholar
• Nagy, L. et al. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol. Cell Biol. 15, 3540–3551 (1995).Original demonstration that RXR activity is required to induce apoptosis in this cell system.
  Article CAS PubMed PubMed Central Google Scholar
• Li, M. et al. Skin abnormalities generated by temporally controlled RXRα mutations in mouse epidermis. Nature 407, 633–636 (2000).
  Article CAS PubMed Google Scholar
• Sun, S. Y. et al. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin. Cancer Res. 6, 1563–1573 (2000).
  CAS PubMed Google Scholar
• Gottardis, M. M. et al. Chemoprevention of mammary carcinoma by lGD1069 (targretin): An RXR-selective ligand. Cancer Res. 56, 5566–5570 (1996).A 90% reduction in tumour burden and tumour incidence by rexinoid treatment in a methylnitrosurea-induced rat mammary carcinoma model. Chronic rexinoid therapy showed no signs of 'retinoid-associated' toxicities.
  CAS PubMed Google Scholar
• Agarwal, V. R., Bischoff, E. D., Hermann, T. & Lamph, W. W. Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand lGD1069 (targretin). Cancer Res. 60, 6033–6038 (2000).
  CAS PubMed Google Scholar
• Gamage, S. D. et al. Efficacy of lGD1069 (targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma. J. Pharmacol. Exp. Ther. 295, 677–681 (2000).
  CAS PubMed Google Scholar
• Miller, V. A. et al. Initial clinical trial of a selective retinoid X receptor ligand, lGD1069. J. Clin. Oncol. 15, 790–795 (1997).
  Article CAS PubMed Google Scholar
• Holmes, W. F., Dawson, M. I., Soprano, R. D. & Soprano, K. J. Induction of apoptosis in ovarian carcinoma cells by AHPN/CD437 is mediated by retinoic acid receptors. J. Cell Physiol. 185, 61–67 (2000).
  Article CAS PubMed Google Scholar
• Sun, S. Y., Yue, P., Hong, W. K. & Lotan, R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (trail)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)- 4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of trail receptors in human lung cancer cells. Cancer Res. 60, 7149–7155 (2000).TRAIL receptor upregulation by an atypical retinoid.
  CAS PubMed Google Scholar
• Sun, S. Y., Yue, P., Hong, W. K. & Lotan, R. Induction of FAS expression and augmentation of FAS/FAS ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res. 60, 6537–6543 (2000).
  CAS PubMed Google Scholar
• Dawson, M. I. et al. Apoptosis induction in cancer cells by a novel analogue of 6-[3-(1- adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid lacking retinoid receptor transcriptional activation activity. Cancer Res. 61, 4723–4730 (2001).
  CAS PubMed Google Scholar
• Li, H. et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 289, 1159–1164 (2000).
  Article CAS PubMed Google Scholar
• Sakaue, M., Adachi, H., Dawson, M. & Jetten, A. M. Induction of EGR-1 expression by the retinoid AHPN in human lung carcinoma cells is dependent on activated ERK1/2. Cell Death Differ. 8, 411–424 (2001).
  Article CAS PubMed Google Scholar
• Chen, Y., Buck, J. & Derguini, F. Anhydroretinol induces oxidative stress and cell death. Cancer Res. 59, 3985–3990 (1999).
  CAS PubMed Google Scholar
• Pandolfi, P. P. Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. Hum. Mol. Genet. 10, 769–775 (2001).
  Article CAS PubMed Google Scholar
• He, L. Z. et al. Distinct interactions of PML–RARα and PLZF–RARα with co-repressors determine differential responses to RA in APL. Nature Genet. 18, 126–135 (1998).
  Article CAS PubMed Google Scholar
• Lin, R. J. et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391, 811–814 (1998).
  Article CAS PubMed Google Scholar
• Grignani, F. et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 391, 815–818 (1998).References 57–59 show that aberrant corepressor interaction of the APL oncofusion proteins leads to stabilization of the HDAC complex and, therefore, enhanced silencing of target genes. Retinoic acid can dissociate the HDAC complex from PML–RARα but not PLZF–RARα, as the latter contains an additional corepressor-binding surface.
  Article CAS PubMed Google Scholar
• Minucci, S. et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol. Cell 5, 811–820 (2000).
  Article CAS PubMed Google Scholar
• Perez, A. et al. PML–RAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J. 12, 3171–3182 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Lin, R. J. & Evans, R. M. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol. Cell 5, 821–830 (2000).References 60–62 show that oligomerization of PML–RARα accounts for its aberrant recruitment of HDAC-containing corepressor complexes.
  Article CAS PubMed Google Scholar
• Guo, A. et al. The function of PML in p53-dependent apoptosis. Nature Cell Biol. 2, 730–736 (2000).
  Article CAS PubMed Google Scholar
• Pearson, M. et al. PML regulates p53 acetylation and premature senescence induced by oncogenic RAS. Nature 406, 207–210 (2000).
  Article CAS PubMed Google Scholar
• Zhong, S. et al. Role of SUMO-1-modified PML in nuclear body formation. Blood 95, 2748–2752 (2000).
  Article CAS PubMed Google Scholar
• Zhong, S., Salomoni, P. & Pandolfi, P. P. The transcriptional role of PML and the nuclear body. Nature Cell Biol. 2, E85–E90 (2000).
  Article CAS PubMed Google Scholar
• Khan, M. M. et al. Role of PML and PML–RARα in MAD-mediated transcriptional repression. Mol. Cell 7, 1233–1243 (2001).
  Article CAS PubMed Google Scholar
• Cheng, G. X. et al. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF–RARα and NPM–RARα. Proc. Natl Acad. Sci. USA 96, 6318–6323 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Lallemand-Breitenbach, V. et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor-α degradation. J. Exp. Med. 193, 1361–1372 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• French, L. E. & Tschopp, J. The trail to selective tumor death. Nature Med. 5, 146–147 (1999).
  Article CAS PubMed Google Scholar
• Fenaux, P., Chomienne, C. & Degos, L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin. Hematol. 38, 13–25 (2001).
  Article CAS PubMed Google Scholar
• Zelent, A. Hot on the trail of acute promyelocytic leukemia. Nature Med. 7, 662–664 (2001).
  Article CAS PubMed Google Scholar
• Bonavida, B., Ng, C. P., Jazirehi, A., Schiller, G. & Mizutani, Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics. Int. J. Oncol. 15, 793–802 (1999).
  CAS PubMed Google Scholar
• Marks, P. A., Richon, V. M. & Rifkind, R. A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl Cancer Inst. 92, 1210–1216 (2000).
  Article CAS PubMed Google Scholar
• Warrell, R. P. Jr, He, L. Z., Richon, V., Calleja, E. & Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl Cancer Inst. 90, 1621–1625 (1998).First report of complete clinical and cytogenetic remission of a relapsed APL patient by treatment with all- trans -retinoic acid in combination with the HDAC inhibitor sodium phenylbutyrate.
  Article CAS PubMed Google Scholar
• Novogrodsky, A. et al. Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer 51, 9–14 (1983).
  Article CAS PubMed Google Scholar
• Minucci, S., Nervi, C., Lo Coco, F. & Pelicci, P. G. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20, 3110–3115 (2001).
  Article CAS PubMed Google Scholar
• Ferrara, F. F. et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61, 2–7 (2001).Restoration of retinoic acid-induced differentiation in non-APL AML blasts by co-treatment with an HDAC inhibitor.
  PubMed Google Scholar
• Cote, S. et al. Altered ligand binding and transcriptional regulation by mutations in the PML/RARα ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. Blood 96, 3200–3208 (2000).
  Article CAS PubMed Google Scholar
• Hong, W. K. & Itri, L. M. in The Retinoids: Biology, Chemistry and Medicine (eds Sporn, M. B., Roberts, A. B. & Goodman, D. S.) 597–658 (Raven, New York, 1994).
  Google Scholar
• Moon, R. C., Mehta, R. G. & Rao, K. J. V. N. in The Retinoids (eds Sporn, M. B., Roberts, A. B. & Goodman, D. S.) 573–595 (Raven, New York, 1994).
  Google Scholar
• Gong, B. & Almasan, A. Genomic organization and transcriptional regulation of human APO2/TRAIL gene. Biochem. Biophys. Res. Commun. 278, 747–752 (2000).
  Article CAS PubMed Google Scholar
• Ma, X. et al. Regulation of interferon and retinoic acid-induced cell death activation through thioredoxin reductase. J. Biol. Chem. 276, 24843–24854 (2001).
  Article CAS PubMed Google Scholar
• List, H. J. et al. Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J. Biol. Chem. 276, 23763–23768 (2001).
  Article CAS PubMed Google Scholar
• Bubulya, A., Wise, S. C., Shen, X. Q., Burmeister, L. A. & Shemshedini, L. c-JUN can mediate androgen receptor-induced transactivation. J. Biol. Chem. 271, 24583–24589 (1996).
  Article CAS PubMed Google Scholar
• Pearce, D., Matsui, W., Miner, J. N. & Yamamoto, K. R. Glucocorticoid receptor transcriptional activity determined by spacing of receptor and nonreceptor DNA sites. J. Biol. Chem. 273, 30081–30085 (1998).
  Article CAS PubMed Google Scholar
• Kamei, Y. et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85, 403–414 (1996).
  Article CAS PubMed Google Scholar
• Caelles, C., Gonzalez-Sancho, J. M. & Munoz, A. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev. 11, 3351–3364 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Rogatsky, I., Logan, S. K. & Garabedian, M. J. Antagonism of glucocorticoid receptor transcriptional activation by the c-JUN N-terminal kinase. Proc. Natl Acad. Sci. USA 95, 2050–2055 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Zhou, X. F., Shen, X. Q. & Shemshedini, L. Ligand-activated retinoic acid receptor inhibits AP-1 transactivation by disrupting c-JUN/c-FOS dimerization. Mol. Endocrinol. 13, 276–285 (1999).
  Article CAS PubMed Google Scholar
• Mann, K. K., Shao, W. & Miller, W. H. Jr. The biology of acute promyelocytic leukemia. Curr. Oncol. Rep. 3, 209–216 (2001).
  Article CAS PubMed Google Scholar
• Branchet, M. C. et al. Topical tretinoin in the treatment of lichen planus and leukoplakia of the oral mucosa. A biochemical evaluation of the keratinization. Ann. Dermatol. Venereol. 121, 464–469 (1994).
  CAS PubMed Google Scholar
• Boisnic, S. et al. Topical tretinoin in the treatment of lichen planus and leukoplakia of the mouth mucosa. A clinical evaluation. Ann. Dermatol. Venereol. 121, 459–463 (1994).
  CAS PubMed Google Scholar
• Peck, G. L. Topical tretinoin in actinic keratosis and basal cell carcinoma. J. Am. Acad. Dermatol. 15, 829–835 (1986).
  Article CAS PubMed Google Scholar
• Meyskens, F. L. Jr, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-_trans_-retinoic acid: a randomized trial. J. Natl Cancer Inst. 86, 539–543 (1994).
  Article PubMed Google Scholar
• Schmutzler, C. & Kohrle, J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 10, 393–406 (2000).
  Article CAS PubMed Google Scholar
• Grunwald, F. et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J. Nucl. Med. 39, 1903–1906 (1998).
  CAS PubMed Google Scholar
• Grunwald, F. et al. Redifferentiation therapy with retinoic acid in follicular thyroid cancer. J. Nucl. Med. 39, 1555–1558 (1998).
  CAS PubMed Google Scholar
• Kelly, W. K. et al. The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer. Clin. Cancer Res. 6, 838–846 (2000).
  CAS PubMed Google Scholar
• Dezube, B. J. AIDS-related Kaposi sarcoma: the role of local therapy for a systemic disease. Arch. Dermatol. 136, 1554–1556 (2000).
  Article CAS PubMed Google Scholar
• Duvic, M. et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase I and II trials. Arch. Dermatol. 136, 1461–1469 (2000).
  Article CAS PubMed Google Scholar
• Mitsuyasu, R. T. AIDS-related Kaposi's sarcoma: current treatment options, future trends. Oncology 14, 867–878 (2000).
  CAS PubMed Google Scholar
• Von Roenn, J. H. & Cianfrocca, M. Treatment of Kaposi's sarcoma. Cancer Treat. Res. 104, 127–148 (2001).
  Article CAS PubMed Google Scholar
• Somos, S. & Farkas, B. Immunomodulatory treatment with low-dose interferon-α and oral retinoic acid in lymphangioma-like Kaposi's sarcoma. Anticancer Res. 20, 541–545 (2000).
  CAS PubMed Google Scholar
• Lawrence, J. A. et al. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. J. Clin. Oncol. 19, 2754–2763 (2001).
  Article CAS PubMed Google Scholar
• Miller, W. H. Jr, et al. A phase I–II study of 9-cis retinoic acid and interferon-α2b in patients with advanced renal-cell carcinoma: an NCIC clinical trials group study. Ann. Oncol. 11, 1387–1389 (2000).
  Article PubMed Google Scholar
• Motzer, R. J. et al. Phase III trial of interferon α-2a with or without 13-_cis_-retinoic acid for patients with advanced renal cell carcinoma. J. Clin. Oncol. 18, 2972–2980 (2000).
  Article CAS PubMed Google Scholar
• Kurie, J. M. et al. Phase I trial of 9-cis retinoic acid in adults with solid tumors. Clin. Cancer Res. 2, 287–293 (1996).
  CAS PubMed Google Scholar
• DiGiovanna, J. J. Retinoid chemoprevention in patients at high risk for skin cancer. Med. Pediatr. Oncol. 36, 564–567 (2001).
  Article CAS PubMed Google Scholar
• DiGiovanna, J. J. Systemic retinoid therapy. Dermatol. Clin. 19, 161–167 (2001).
  Article CAS PubMed Google Scholar
• Lee, J. J. et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin. Cancer Res. 6, 1702–1710 (2000).First comprehensive tool for assessing cancer risk of patients with oral premalignant lesions. It incorporates medical/demographic variables, epidemiological factors, and cellular and molecular biomarkers.
  CAS PubMed Google Scholar
• Beenken, S. W. et al. Transforming growth factor-α (TGF-α) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid. Head Neck 21, 566–573 (1999).
  Article CAS PubMed Google Scholar
• Toma, S., Mangiante, P. E., Margarino, G., Nicolo, G. & Palumbo, R. Progressive 13-_cis_-retinoic acid dosage in the treatment of oral leukoplakia. Eur. J. Cancer B Oral Oncol. 28B, 121–123 (1992).
  Article CAS PubMed Google Scholar
• Hong, W. K. et al. 13-_cis_-retinoic acid in the treatment of oral leukoplakia. N. Engl. J. Med. 315, 1501–1505 (1986).
  Article CAS PubMed Google Scholar
• Shin, D. M. et al. Accumulation of p53 protein and retinoic acid receptor-β in retinoid chemoprevention. Clin. Cancer Res. 3, 875–880 (1997).
  CAS PubMed Google Scholar
• Kraemer, K. H., DiGiovanna, J. J., Moshell, A. N., Tarone, R. E. & Peck, G. L. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N. Engl. J. Med. 318, 1633–1637 (1988).
  Article CAS PubMed Google Scholar
• Kraemer, K. H., DiGiovanna, J. J. & Peck, G. L. Chemoprevention of skin cancer in xeroderma pigmentosum. J. Dermatol. 19, 715–718 (1992).
  Article CAS PubMed Google Scholar
• Hong, W. K. et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 323, 795–801 (1990).13- cis retinoic acid treatment reduced the risk for second primary tumours by 20% (2 versus 12 patients) in a cohort of 103 patients who were disease free after primary treatment.
  Article CAS PubMed Google Scholar
• Benner, S. E., Pajak, T. F., Lippman, S. M., Earley, C. & Hong, W. K. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J. Natl Cancer Inst. 86, 140–141 (1994).
  Article CAS PubMed Google Scholar
• Shin, D. M. et al. Combined interferon-α, 13-_cis_-retinoic acid, and α-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J. Clin. Oncol. 19, 3010–3017 (2001).
  Article CAS PubMed Google Scholar
• Matthay, K. K. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-_cis_-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341, 1165–1173 (1999).
  Article CAS PubMed Google Scholar
• Lippman, S. M. et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J. Natl Cancer Inst. 93, 605–618 (2001).
  Article CAS PubMed Google Scholar
• Recchia, F. et al. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study. Anticancer Res. 20, 1985–1990 (2000).
  CAS PubMed Google Scholar
• Park, T. K. et al. Interferon-α 2α, 13-_cis_-retinoic acid and radiotherapy for locally advanced carcinoma of the cervix: a pilot study. Eur. J. Gynaecol. Oncol. 19, 35–38 (1998).
  CAS PubMed Google Scholar
• Lippman, S. M. et al. 13-_cis_-retinoic acid plus interferon-α-2α: highly active systemic therapy for squamous cell carcinoma of the cervix. J. Natl Cancer Inst. 84, 241–245 (1992).
  Article CAS PubMed Google Scholar
• Cohen, M. H. et al. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 6, 4–11 (2001).
  Article CAS PubMed Google Scholar
• Duvic, M. & Cather, J. C. Emerging new therapies for cutaneous T-cell lymphoma. Dermatol. Clin. 18, 147–156 (2000).
  Article CAS PubMed Google Scholar
• Hurst, R. E. Bexarotene ligand pharmaceuticals. Curr. Opin. Investig. Drugs 1, 514–523 (2000).
  CAS PubMed Google Scholar
• Khuri, F. R. et al. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 19, 2626–2637 (2001).
  Article CAS PubMed Google Scholar
• Camerini, T. et al. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J. Clin. Oncol. 19, 1664–1670 (2001).
  Article CAS PubMed Google Scholar
• Decensi, A. & Costa, A. Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer. Eur. J. Cancer 36, 694–709 (2000).
  Article CAS PubMed Google Scholar
• McPherson, K., Steel, C. M. & Dixon, J. M. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 321, 624–628 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Torrisi, R. & Decensi, A. Fenretinide and cancer prevention. Curr. Oncol. Rep. 2, 263–270 (2000).
  Article CAS PubMed Google Scholar
• Tradati, N. et al. Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR). Cancer Lett. 76, 109–111 (1994).
  Article CAS PubMed Google Scholar
• Ruidi, C. et al. Chemoprevention of cancer of uterine cervix: a study on chemoprevention of retinamide II from cervical precancerous lesions. J. Cell Biochem. Suppl. 29, 140–143 (1997).
  Article Google Scholar
• Reynolds, C. P. Differentiating agents in pediatric malignancies: retinoids in neuroblastoma. Curr. Oncol. Rep. 2, 511–518 (2000).
  Article CAS PubMed Google Scholar
• Veronesi, U. & Decensi, A. Retinoids for ovarian cancer prevention: laboratory data set the stage for thoughtful clinical trials. J. Natl Cancer Inst. 93, 486–488 (2001).
  Article CAS PubMed Google Scholar
• Zhang, D., Holmes, W. F., Wu, S., Soprano, D. R. & Soprano, K. J. Retinoids and ovarian cancer. J. Cell Physiol. 185, 1–20 (2000).
  Article CAS PubMed Google Scholar
• Clifford, J. L. et al. Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. Cancer Epidemiol. Biomarkers Prev. 10, 391–395 (2001).
  CAS PubMed Google Scholar
• Thaller, C. et al. Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration. J. Clin. Oncol. 18, 3804–3808 (2000).
  Article CAS PubMed Google Scholar
• Weiss, H. L. et al. Bayesian monitoring of a phase II chemoprevention trial in high-risk cohorts for prostate cancer. Urology 57, 220–223 (2001).
  Article CAS PubMed Google Scholar
• Muto, Y. et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N. Engl. J. Med. 334, 1561–1567 (1996).Polyprenoic acid reduced the risk for second primary hepatocellular carcinomas by 22% (12 versus 22 patients) in a cohort of 89 patients who were free of disease after surgical resection of a primary hepatoma or the percutaneous injection of ethanol.
  Article CAS PubMed Google Scholar
• Muto, Y., Moriwaki, H. & Saito, A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N. Engl. J. Med. 340, 1046–1047 (1999).
  Article CAS PubMed Google Scholar
• DiSilvestro, P. A., DiSilvestro, J. M., Lenhardt, W., Pfahl, M. & Mannel, R. S. Treatment of cervical intraepithelial neoplasia levels 2 and 3 with adapalene, a retinoid-related molecule. J. Lower Genital Tract Dis. 5, 33–37 (2001).
  CAS Google Scholar